Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort

Date
2015
Author
STEINSSON, Kristjan
BAE, Sang-Cheol
SANCHEZ-GUERRERO, Jorge
ROMERO-DIAZ, Juanita
Gordon, Caroline
WALLACE, Daniel J.
Clarke, Ann E.
Bernatsky, Sasha
GINZLER, Ellen M.
Isenberg, David A.
Rahman, Anisur
MERRILL, Joan T.
ALARCON, Graciela S.
FESSLER, Barri J.
Fortin, Paul R.
HANLY, John G.
Petri, Michelle
Dooley, Mary Anne
MANZI, Susan
KHAMASHTA, Munther A.
Ramsey-Goldman, Rosalind
ZOMA, Asad A.
Sturfelt, Gunnar K.
Nived, Ola
ARANOW, Cynthia
MACKAY, Meggan
RAMOS-CASALS, Manuel
van Vollenhoven, Ronald F.
Peschken, Christine A.
Bruce, Ian N.
Inanc, Murat
KALUNIAN, Kenneth C.
RUIZ-IRASTORZA, Guillermo
Lim, S. Sam
KAMEN, Diane L.
Parker, Ben
Urowitz, Murray B.
Gladman, Dafna D.
Lunt, Mark
Donn, Rachelle
Metadata
Show full item record
Abstract
Background The metabolic syndrome (MetS) may contribute to the increased cardiovascular risk in systemic lupus erythematosus (SLE). We examined the association between MetS and disease activity, disease phenotype and corticosteroid exposure over time in patients with SLE.
URI
http://hdl.handle.net/20.500.12627/7142
https://doi.org/10.1136/annrheumdis-2013-203933
Collections